Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IntraLuminal completes $20 million financing:

This article was originally published in Clinica

Executive Summary

IntraLuminal, which is developing products for the crossing and recanalisation of total occlusions, has completed the first tranche of a two-stage financing round. $20m is available immediately, with a further $10m triggered by milestones. The funds will be used for a continued rollout of the Carlsbad, California-based company's Safe-Cross TO crossing system, the selected introduction of the first generation SafeSteer system in the US and development of the second and next generation systems. Of the 4.3 million coronary artery patients worldwide undergoing coronary and peripheral diagnostic procedures annually, 1.2m will have one or more total occlusions, IntraLuminal says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel